Charles Reay Mackay

G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia.

The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia.